Jefferies analyst Brandon Couillard raised his price target for Bio-Rad Laboratories to $225 from $200 after performing an analysis on the company's multi-year valuation creation opportunity. A "trough valuation on trough earnings make BIO the most under-appreciated asset in our universe," Couillard tells investors in a research note. The company is "on the cusp of a profit margin & ROIC inflection that is now investable," the analyst argues. He believes expectations for Bio are low and keeps a Buy rating on the name. Bio-Rad, a manufacturer and distributor of life science research and clinical diagnostics products, closed yesterday up 52c to $151.66.